The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
© Royal Society of Chemistry Registered charity number: 207890
Site powered by Webvision Cloud